Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Pamiparib +1 More for Renal Cell Carcinoma
Recruiting1 awardPhase 2
Los Angeles, California
This trial is testing pamiparib, a drug that inhibits proteins that help repair DNA mutations, in combination with temozolomide, a chemotherapy drug, to see if it is effective in treating patients with hereditary leiomyomatosis and renal cell cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.